Health & Fitness
Health and FitnessHealth and Fitness 
Wed, January 4, 2012
Teva to Restart Generic Animal Vaccine Production at Missouri Plant Following $14 Million FDA Compliance Investment, an Industr
January 04, 2012 06:40 ET
Teva to Restart Generic Animal Vaccine Production at Missouri Plant Following $14 Million FDA Compliance Investment, an Industrial Info News Alert
SUGAR LAND, TX--(Marketwire - Jan 4, 2012) - Researched by Industrial Info Resources (Sugar Land, Texas) -- In 2009, [ Teva Animal Health Incorporated ] (NASDAQ:TEVA) (Petah Tikva, Israel), the largest U.S. manufacturer of [ generic animal drugs ], was ordered by the U.S. Food and Drug Administration (FDA) to cease operations at its facility in St. Joseph, Missouri. The subsidiary of Israel-based Teva Pharmaceuticals had failed to comply with current Good Manufacturing Practice (cGMP) regulations in its quality control, employee training and manufacturing practices. However, the compliance project is slowly winding down, and the plant should resume operations in the first quarter of this year.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News at [ http://www.industrialinfo.com/showAbstract.jsp?newsitemID=193665&refer=marketwire ], or browse other breaking industrial news stories at [ www.industrialinfo.com ].
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, and eight offices outside of North America, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the [ www.industrialinfo.com ] "[ Contact Us ]" page.